Electra director converts 255K preferred shares
Electra Therapeutics, Inc. (ETRA) reported that director Nancy Stagliano converted all of her Series A Convertible Preferred Stock into Common Stock in connection with the closing of the company’s initial public offering.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reported that director Nancy Stagliano converted all of her Series A Convertible Preferred Stock into Common Stock in connection with the closing of the company’s initial public offering. On September 21, 2026, 255,635 preferred shares automatically converted into 255,635 Common Shares on a 1-for-1 basis without further consideration, leaving her with 255,635 Common Shares held directly and no remaining Preferred Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
255,635 shares exercised/converted
Exercise
2 txns
Insider
Stagliano Nancy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Convertible Preferred Stock F1 | 255,635 | -- | -- |
| Conversion | Common Stock F1 | 255,635 | -- | -- |
Holdings After Transaction:
Series A Convertible Preferred Stock — 0 contracts (Direct);
Common Stock — 255,635 shares (Direct)
Footnotes (1)
- F1. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
Key Figures
Preferred Shares Converted: 255,635 shares
Common Shares Received: 255,635 shares
Common Shares Held After Transaction: 255,635 shares
+2 more
5 metrics
Preferred Shares Converted
255,635 shares
Series A Convertible Preferred Stock converted on September 21, 2026
Common Shares Received
255,635 shares
Common Stock received upon conversion of Series A Convertible Preferred Stock
Common Shares Held After Transaction
255,635 shares
Director’s direct Common Stock holdings following the IPO-related conversion
Preferred Shares Held After Transaction
0 shares
Series A Convertible Preferred Stock position after automatic IPO conversion
Conversion Date
September 21, 2026
Date of automatic conversion tied to the issuer’s initial public offering
Key Terms
Series A Convertible Preferred Stock, initial public offering, Common Stock, automatic conversion
4 terms
Series A Convertible Preferred Stock financial
"Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
initial public offering financial
"converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Common Stock financial
"converted automatically into 1 share of Common Stock upon the closing"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
automatic conversion financial
"Each share of Series A Convertible Preferred Stock ... converted automatically into 1 share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Electra Therapeutics (ETRA) report for Nancy Stagliano?
Electra Therapeutics reported that director Nancy Stagliano converted 255,635 shares of Series A Convertible Preferred Stock into 255,635 shares of Common Stock on September 21, 2026, in connection with the closing of the company’s initial public offering.
What happened to Nancy Stagliano’s Series A Convertible Preferred Stock in ETRA?
Each share of Nancy Stagliano’s Series A Convertible Preferred Stock automatically converted into 1 share of Common Stock upon the closing of Electra Therapeutics’ initial public offering, without payment of further consideration, resulting in 0 preferred shares remaining.
Was the Electra Therapeutics (ETRA) insider transaction under a Rule 10b5-1 trading plan?
No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions. The conversion occurred automatically upon the closing of Electra Therapeutics’ initial public offering, as described in the footnote.
What is the conversion rate of Electra Therapeutics’ Series A Convertible Preferred Stock reported here?
The filing states that each share of Series A Convertible Preferred Stock converted automatically into 1 share of Common Stock upon the closing of Electra Therapeutics’ initial public offering, and that the Preferred Stock had no expiration date before conversion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
